Vitura Health (ASX:VIT) announced the appointment of Justin James as its new CEO.
James, a veteran healthcare leader, is scheduled to officially take the helm on June 1, following a rigorous global search.
He succeeds the outgoing leadership at a pivotal moment for the digital health platform, which is increasingly focusing on the medicinal cannabis and psychedelic-assisted therapy markets.
James transitions to Vitura from a five-year tenure as CEO of the Health Insurance Fund of Australia.
During his time at HIF, he was credited with executing a significant financial turnaround, growing annual revenue to upwards of $180 million while delivering consistent net profits through disciplined capital management.
James was a pioneer in the Australian private health sector for expanding member access to medicinal cannabis and MDMA-assisted treatments—specialities that align directly with Vitura’s core business model.
His leadership at HIF saw employee engagement skyrocket from 36% to 79%, a metric Vitura’s Independent Chair, Robert Iervasi, highlighted as crucial for the company’s "Strengthening Team & Company Culture" initiative.
James is expected to accelerate Vitura’s next phase of commercial transformation and patient access expansion.
At the time of reporting, Vitura Health’s share price was $0.038.